This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.
Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.
Aged ≥18 years at the time of signing the written informed consent.
Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).
Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.
Uncontrolled primary hypertension.
Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation.
Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).
Expected life expectancy <1 years.
Patients with hypertrophic cardiomyopathy
Cohort
Prospective
No interventions were applied to the patients.
Other interventionNo interventions were applied to the patients.
Composite Cardiovascular Endpoints
Number of Participants with a composite cardiovascular endpoint consisting of ischemic stroke, heart failure hospitalization, and cardiovascular death
All-cause mortality
Rate of death resulting from any cause, encompassing both disease-related and non-disease-related factors
Cardiovascular death
Rate of death resulting from cardiac diseases
New-onset arrhythmia
Number of Participants with new-onset arrhythmia
Sudden cardiac death (SCD)
Number of Participants suffer from sudden cardiac death
Click on the lead sponsor to view all of their trials.
